28058039|t|Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients
28058039|a|Hepatitis C virus (HCV) is a significant global public health problem with >185 million infections worldwide. A series of genome-wide association studies (GWAS) has identified IL-28B polymorphisms as a predictor of sustained virologic response (SVR), as well as spontaneous clearance in chronic HCV genotype 1 patients. The objective of this work was to evaluate the prevalence of IL-28B rs12979860 and rs8099917 polymorphisms in Cuban chronic HCV patients. The study cohort included 73 chronic HCV patients treated with concomitant administration of CIGB-230 and nonpegylated IFN-α plus ribavirin (non-pegIFN-α / R) antiviral therapy. The genotype distribution of IL-28B rs12979860CC, - CT, and - TT was 29, 41, and 30%, respectively, and the distribution for rs8099917TT, - TG, and - GG was 63, 31, and 5%, respectively. The allele frequencies for rs12979860C and - T alleles were 51 and 49%, respectively, and for rs8099917G and - T alleles, the values were 21 and 79%, respectively. SVR rates were 55, 42, and 35% for rs12979860CC, - CT, and - TT, respectively, and 52, 30, and 25% for rs8099917TT, - GT, and - GG, respectively. The combined assessment of both single nucleotide polymorphisms (SNPs) resulted in 3 major genotypes (rs12979860CC / rs8099917TT, rs12979860CT / rs8099917TT, and rs12979860CT / rs8099917GG) with a frequency of 30.1, 21.9, and 20.5%, respectively. In patients with heterozygous variant rs12979860CT, the additional genotyping of rs8099917 contributed to increase the SVR rate. It is concluded that in Cuban HCV - infected patients, the responder homogeneous variant rs8099917TT is the most frequent genotype. The simultaneous genotyping of 2 IL-28B SNPs could improve the prediction of SVR contributing to better therapeutic decisions and treatment management.
28058039	0	10	Assessment	T058	C0220825
28058039	14	19	IL-28	T028	C1425475
28058039	21	31	rs12979860	T028	C3476056
28058039	36	45	rs8099917	T028	C0678941
28058039	46	59	Polymorphisms	T045	C0032529
28058039	65	71	Cohort	T098	C0599755
28058039	75	80	Cuban	T098	C1553379
28058039	81	104	Chronic HCV Genotype 1b	T047	C4049394
28058039	105	113	Patients	T101	C0030705
28058039	114	131	Hepatitis C virus	T005	C0220847
28058039	133	136	HCV	T005	C0220847
28058039	143	154	significant	T078	C0750502
28058039	155	161	global	T080	C2348867
28058039	162	183	public health problem	T078	C0021788
28058039	202	212	infections	T046	C3714514
28058039	213	222	worldwide	T098	C2700280
28058039	226	232	series	T081	C0205549
28058039	236	267	genome-wide association studies	T063	C2350277
28058039	269	273	GWAS	T063	C2350277
28058039	290	296	IL-28B	T028	C1425475
28058039	297	310	polymorphisms	T045	C0032529
28058039	316	325	predictor	T078	C2698872
28058039	329	357	sustained virologic response	T033	C4050171
28058039	359	362	SVR	T033	C4050171
28058039	376	387	spontaneous	T169	C0205359
28058039	388	397	clearance	T080	C0449297
28058039	401	423	chronic HCV genotype 1	T047	C4049394
28058039	424	432	patients	T101	C0030705
28058039	438	447	objective	T170	C0018017
28058039	456	460	work	T057	C0043227
28058039	468	476	evaluate	T058	C0220825
28058039	481	491	prevalence	T081	C0220900
28058039	495	512	IL-28B rs12979860	T028	C3476056
28058039	517	526	rs8099917	T028	C0678941
28058039	527	540	polymorphisms	T045	C0032529
28058039	544	549	Cuban	T098	C1553379
28058039	550	557	chronic	T079	C0205191
28058039	558	561	HCV	T005	C0220847
28058039	562	570	patients	T101	C0030705
28058039	576	588	study cohort	T081	C0009247
28058039	601	608	chronic	T079	C0205191
28058039	609	612	HCV	T005	C0220847
28058039	613	621	patients	T101	C0030705
28058039	622	634	treated with	T061	C0332293
28058039	635	646	concomitant	T079	C0521115
28058039	647	661	administration	T061	C1533734
28058039	665	673	CIGB-230	T114,T121,T129	C3851847
28058039	678	696	nonpegylated IFN-α	T116,T121,T129	C0002199
28058039	702	711	ribavirin	T114,T121	C0035525
28058039	713	725	non-pegIFN-α	T116,T121,T129	C0002199
28058039	728	729	R	T114,T121	C0035525
28058039	731	748	antiviral therapy	T061	C0280274
28058039	754	762	genotype	T032	C0017431
28058039	763	775	distribution	T169	C1704711
28058039	779	798	IL-28B rs12979860CC	T028	C0678941
28058039	802	804	CT	T028	C0678941
28058039	812	814	TT	T028	C0678941
28058039	858	870	distribution	T169	C1704711
28058039	875	886	rs8099917TT	T028	C0678941
28058039	890	892	TG	T028	C0678941
28058039	900	902	GG	T028	C0678941
28058039	941	959	allele frequencies	T081	C0017270
28058039	964	975	rs12979860C	T028	C0678941
28058039	982	983	T	T028	C0678941
28058039	984	991	alleles	T028	C0002085
28058039	1031	1041	rs8099917G	T028	C0678941
28058039	1048	1049	T	T028	C0678941
28058039	1050	1057	alleles	T028	C0002085
28058039	1063	1069	values	T080	C0042295
28058039	1101	1104	SVR	T033	C4050171
28058039	1105	1110	rates	T081	C1521828
28058039	1136	1148	rs12979860CC	T028	C0678941
28058039	1152	1154	CT	T028	C0678941
28058039	1162	1164	TT	T028	C0678941
28058039	1204	1215	rs8099917TT	T028	C0678941
28058039	1219	1221	GT	T028	C0678941
28058039	1229	1231	GG	T028	C0678941
28058039	1260	1270	assessment	T058	C0220825
28058039	1279	1310	single nucleotide polymorphisms	T086	C0752046
28058039	1312	1316	SNPs	T086	C0752046
28058039	1318	1326	resulted	T169	C1274040
28058039	1338	1347	genotypes	T032	C0017431
28058039	1349	1361	rs12979860CC	T028	C0678941
28058039	1364	1375	rs8099917TT	T028	C0678941
28058039	1377	1389	rs12979860CT	T028	C0678941
28058039	1392	1403	rs8099917TT	T028	C0678941
28058039	1409	1421	rs12979860CT	T028	C0678941
28058039	1424	1435	rs8099917GG	T028	C0678941
28058039	1444	1453	frequency	T081	C1705502
28058039	1497	1505	patients	T101	C0030705
28058039	1511	1523	heterozygous	T032	C0019425
28058039	1524	1531	variant	T028	C0678941
28058039	1532	1544	rs12979860CT	T028	C0678941
28058039	1561	1571	genotyping	T059,T063	C3178894
28058039	1575	1584	rs8099917	T028	C0678941
28058039	1600	1608	increase	T169	C0442805
28058039	1613	1616	SVR	T033	C4050171
28058039	1617	1621	rate	T081	C1521828
28058039	1647	1652	Cuban	T098	C1553379
28058039	1653	1656	HCV	T005	C0220847
28058039	1659	1667	infected	T033	C0439663
28058039	1668	1676	patients	T101	C0030705
28058039	1682	1691	responder	T033	C0919876
28058039	1692	1703	homogeneous	T080	C1881065
28058039	1704	1711	variant	T028	C0678941
28058039	1712	1723	rs8099917TT	T028	C0678941
28058039	1736	1744	frequent	T079	C0332183
28058039	1745	1753	genotype	T032	C0017431
28058039	1759	1771	simultaneous	T079	C0521115
28058039	1772	1782	genotyping	T059,T063	C3178894
28058039	1788	1794	IL-28B	T028	C1425475
28058039	1795	1799	SNPs	T086	C0752046
28058039	1806	1813	improve	T033	C0184511
28058039	1818	1828	prediction	T078	C0681842
28058039	1832	1835	SVR	T033	C4050171
28058039	1859	1870	therapeutic	T169	C0302350
28058039	1871	1880	decisions	T041	C0679006
28058039	1885	1905	treatment management	T058	C0030677